← Statins × liver & masld

SynthesisEuropean heart journal2013

Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis.

Wanyin Hou et al.PubMed ↗Publisher ↗

What the trial testedas reported · 429 people · 2013

Range includes no effect

No clear effect on liver & MASLD

+13%−8% to +39%

Bigger than 2 in 10 on the map

As reported

RR 1.13, 95% CI 0.92–1.39

Range includes no effect

No clear effect on liver & MASLD

+2%−5% to +9%

Smaller than almost all on the map

As reported

RR 1.02, 95% CI 0.95–1.09

Two numbers in the abstract

the abstract, start to end

… by statins, including hepatic (RR 1.13, 95% CI 0.92-1.39) or muscular disorders (RR 1.02, 95% CI 0.95-1.09).

← favours treatmentfavours comparator →
could be chance
Liver & masld
RR 1.130.92–1.39
Liver & masld
RR 1.020.95–1.09
StatinsLiver & MASLD
1 / 3

63 papers cite itlatest 60 shown

2013
…
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

The trial

NCT03007524phase 480 enrolled2016
Full record →Abstract, authors, funding and every citing paper · PMID 23470492